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ABSTRACT 
EFFECT OF SOY ISOFLAVONE AND SOY LECITHIN ON ENDOTHELIAL FUNCTION IN 
HEALTHY POSTMENOPAUSAL WOMEN 
Meg Pearson, Valentine Njike, Marian Evans, Martha Huxley, and David L. Katz. Department of 
Epidemiology and Public Health, Yale University, School of Medicine, New Haven, CT. 
 
The purpose of this study was to assess the effects of soy isoflavone protein concentrate and soy 
lecithin on endothelial function measured as flow mediated dilation (FMD) of the brachial artery 
in healthy postmenopausal women.  In this randomized, double-blind, placebo controlled 
crossover trial, twenty-five subjects (mean age 61 years; BMI 25.46 kg/m2) were recruited from 
the general population of southwestern Connecticut.  Subjects underwent endothelial function 
testing using high frequency ultrasound at baseline and following 4 weeks of each randomly 
assigned treatment with intervening 4-week washout periods.  Treatment assignment included: 
soy isoflavone protein (SP, 25gm/day) or soy lecithin (SL, 20gm/day) alone with placebo for the 
alternative treatment; both active treatments; or double placebo. Main outcome measures were 
endothelial function, assessed as flow mediated dilation (FMD) of the brachial artery, and serum 
lipids. 
 
Twenty-two women completed the trial.  Baseline FMD (pre-treatment FMD) was 8.60 + 7.20. 
No statistically significant (P > 0.05) difference was seen in FMD between treatment 
assignments. A trend was suggested, however, with FMD highest after treatment with both soy 
protein and lecithin (7.50 + 9.85), followed by soy protein and placebo lecithin  (5.51 + 10.11), 
placebo protein and soy lecithin (5.35 + 6.13), and lowest after double placebo (4.53 + 7.84). Soy 
isoflavone protein and soy lecithin significantly (P < 0.05) increased HDL/LDL relative to 
baseline value (soy isoflavone protein and soy lecithin, 0.64 ± 0.19; soy isoflavone protein and 
placebo lecithin, 0.58 ± 0.17; placebo protein and soy lecithin, 0.65 ± 0.18; baseline, 0.49 ± 0.15).  
 
In this sample of healthy postmenopausal women, soy isoflavone protein and soy lecithin 
significantly improved the lipid profile.  A favorable influence on endothelial function by soy 
isoflavone and soy lecithin was suggested but could not be confirmed statistically, possibly due to 
small sample size, timing of testing, dose, or delivery vehicle.  Although soy protein consumption 
is generally recommended as part of a heart-healthy diet, its favorable effects on cardiovascular 
disease risk factors such as endothelial function and lipids have not been consistently 
demonstrated in clinical trials, and further investigation into its effects on specific cardiovascular 
outcomes is necessary before a substantial cardioprotective role for soy protein can be asserted.  
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INTRODUCTION 
DEFINITIONS 
Terminology related to postmenopausal hormone therapy is inconsistent and potentially 
confusing.  The following terminology will be used in this paper, as proposed in the October 2004 
position statement by the North American Menopause Society.1 
ET   estrogen therapy 
EPT   combined estrogen-progestogen therapy 
HT   hormone therapy (encompassing both ET and EPT) 
CC-EPT continuous-combined estrogen-progestogen therapy (daily administration 
of both estrogen and progestogen) 
CS-EPT continuous-sequential estrogen-progestogen therapy (estrogen daily, with 
progestogen added on a set sequence) 
progestogen encompassing both progesterone and progestin 
 
OVERVIEW OF MENOPAUSE  
Menopause is the permanent cessation of menstruation and ovarian follicular production 
of estrogens and progesterone.  The mean age at menopause is 51 years, and 95% of women 
reach menopause between the ages of 45 and 55.2  The climacteric is the epoch of endocrinal, 
somatic, and psychological changes accompanying the menopausal transition (MT).  The onset of 
the MT is defined as the first break in menstrual cyclicity, in a woman whose cycles have 
previously been regular.  Early menopausal transition continues up until the third consecutive 
month of amenorrhea, at which point a woman is said to have entered the late menopausal 
transition.3  In most women, the final menstrual period (FMP) occurs within 4 years of the 
beginning the late menopausal transition.4  The FMP marks the beginning of postmenopause, 
although it is not officially recognized until 12 month of amenorrhea have elapsed.  The term 
perimenopausal includes the menopausal transition and the first 12 months of postmenopause.5 
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The volume of the ovary and its follicle pool decline throughout reproductive life, with 
significant declines beginning after the age of 30 and continuing until the age of 70.6, 7  When the 
follicle cohort diminishes to a critical level, cycle irregularities ensue, signaling the onset of the 
MT.  During the early MT, when the ovary still contains sufficient follicles, it is considered to be 
in a state of compensated failure.  The elevated FSH levels can result in a shortened follicular 
phase and hyperestrogenemia.  The late phase of the MT is characterized by increasing levels of 
FSH and low levels of estrogen, termed hypergonadotrophic hypogonadism.7 
MENOPAUSAL SYMPTOMS 
Symptoms directly related to declining ovarian endocrine function include vaginal 
dryness and vasomotor symptoms such as hot flashes and night sweats.  Symptoms suggestive of 
normo- or hyperestrogenemia, such as breast tenderness, tend to occur with greatest frequency 
during the early MT.  Urogential atrophy and vasomotor instability are suggestive of low estrogen 
levels, and are associated with the late MT.8  The etiology of hot flashes is unknown, but it is 
thought that estrogen withdrawal leads to a centrally-mediated thermoregulatory dysfunction at 
the level of the hypothalamus.9 
Menopausal estrogen loss is associated with at least two pathologies: osteoporosis and 
cardiovascular disease. A detailed discussion of osteoporosis is beyond the scope of this project, 
but a brief overview of the etiology and clinical management of menopause-related bone loss is 
warranted. 
OSTEOPOROSIS   
Osteoporosis is characterized by global skeletal fragility in conjunction with low bone 
mineral density, susceptibility to fracture with minimal trauma, and disruption of skeletal micro-
architecture.  Osteoporosis results from multiple causes, including physical, genetic and 
nutritional factors, in addition to estrogen loss with menopause.  Skeletal status in adulthood is 
determined by the peak bone mass at skeletal maturity (age 28) minus the bone mass that is lost 
thereafter.10 
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The daily loss of calcium among premenopausal women is 20 mg, and it increases to 
approximately 60 mg per day as women enter the menopausal transition.11  The estrogen loss with 
menopause results in increased bone resorption and decreased bone formation, as well as 
increased urinary excretion and decreased intestinal absorption of calcium.  Decreased estrogen 
stimulates osteoclast activity, leading to increased bone resorption and elevated serum calcium.  
Hypercalcemia inhibits parathyroid hormone release, thereby decreasing synthesis of 1,25-
dihydroxyvitamin D by the kidney and absorption of calcium in the intestine. 
Treatment for all postmenopausal women should include a daily intake of 1500 mg of 
elemental calcium and 800 mg vitamin D (most women require supplements of 1000mg calcium 
and 400 IU vitamin D to reach this), exercise for at least 20 minutes daily, and smoking cessation.  
For many years, the first-line pharmacologic treatment for menopause-related bone loss was 
hormone therapy (HT), but concern for possible increased risks of breast cancer and 
cardiovascular disease with HT (discussed in detail below), has led to a change in clinical 
practice.  First-line treatment of postmenopausal osteoporosis is usually a bisphosphonate, such as 
alendronate or risedronate, whose efficacy in preventing and reversing bone loss is half that of 
hormone therapy.  The selective estrogen receptor modulator (SERM) raloxifene is also approved 
for prevention and treatment of postmenopausal osteoporosis, although its efficacy is less than 
estrogen’s.  Other options include calcitonin and parathyroid hormone.12 
CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among 
postmenopausal women in westernized societies.13, 14  CVD accounts for nearly half of all deaths 
in women, and 50% of these deaths are due to coronary heart disease (CHD).15, 16  Women are 
largely protected from CHD before menopause, but their risk increases rapidly following 
menopause.17  Clinical and experimental studies indicate that the increased risk may be largely 
attributable to the decline of endogenous estrogens.18  The Framingham study showed that the 
incidence of CVD is higher among postmenopausal than in premenopausal women, even among 
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women of the same age.  Women who experience early menopause, both naturally and surgically 
(bilateral oophorectomy), also have increased risk of coronary events.19 
Cardiovascular disease comprises three major areas of disease: coronary heart disease 
(manifested clinically as myocardial infarction, angina pectoris, heart failure, and coronary 
death), cerebrovascular disease (manifested as stroke and transient cerebral ischemia), and 
peripheral vascular disease (manifested as intermittent claudication).  The primary pathological 
process behind these disease states is atherosclerosis, a type of arteriosclerosis (hardening of the 
arteries) characterized by irregular deposition of lipids in the intima of large and medium-sized 
arteries. 
The atherosclerotic process begins in childhood with the development of fatty streaks, 
which progress to fibrous plaques that may ultimately cause ischemic damage through thrombotic 
occlusions.  Fatty streaks are focal regions of intimal thickening consisting of foam cells (lipid-
laden macrophages and monocytes), T lymphocytes, and vascular smooth muscle cells that have 
proliferated and migrated within the intima.  Further accumulation of smooth muscle cells, 
macrophages, connective tissue, and lipid deposits transforms the fatty streak into a fibrous 
plaque.  Advanced lesions are characterized by reactive fibrous caps, revascularization, and a 
necrotic core consisting of leukocytes, lipids and debris. 
Atherosclerosis is caused by numerous, interrelated factors, including dyslipidemia, 
endothelial dysfunction, smoking, and inflammatory factors and oxidative damage.  Of these, 
dyslipidemia and endothelial function are of particular relevance to postmenopausal women and 
are the focus of this study.   
Dyslipidemia is known to be associated with atherosclerosis in both men and women, and 
has also been linked to menopause.  High levels of low density lipoprotein (LDL) and low levels 
of high density lipoprotein (HDL) are established risk factors for atherosclerosis.  Circulating 
LDL is taken up by macrophages and monocytes to form foam cells that contribute to the 
formation of plaque.  When oxidized, LDL particles are more readily phagocytosed by 
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macrophages.20  In addition to oxidizing LDL particles, oxygen-derived free radicals also 
inactivate NO in the vessel wall.21  CVD is associated with both increased levels of oxidized LDL 
and increased risk of in vitro LDL oxidation.22  Premenopausal women have low LDL and high 
HDL cholesterol levels compared to men of the same age.  After menopause, women’s LDL 
cholesterol and lipoprotein (a) levels climb, and HDL cholesterol levels fall, giving them a more 
atherogenic lipid profile.18, 23, 24  These unfavorable changes in lipid profile at menopause are 
independent of BMI, age, and other potential confounding variables,23 and may contribute to the 
increased incidence of CVD in postmenopausal women.   
 
OVERVIEW OF ENDOTHELIAL FUNCTION 
Menopause is also associated with impaired endothelial function (EF).25  The 
endothelium, the single layer of cells lining blood vessels, performs a wide array of vital 
homeostatic functions.  A healthy endothelium regulates vascular tone and proliferation, 
thrombosis and thrombolysis, and platelet and leukocyte interactions with the vessel wall.26, 27 A 
dysfunctional endothelium has been shown in experimental and clinical studies to lose these 
salutary effects,26 leading to thrombosis, vasospasm and vasoconstriction, and abnormal vascular 
proliferation.  Endothelial dysfunction is associated with traditional cardiac risk factors, including 
hypertension, hypercholesterolemia, cigarette smoking, and diabetes mellitus.28  It is widely 
viewed as an indicator of coronary risk.29  Risk factor modification, including reduction of LDL 
levels, smoking cessation and blood pressure reduction has been shown to improve endothelial 
function.28 
Endothelial function refers to arterial vasomotor responses mediated by the release of 
chemicals including nitric oxide (vasodilating) and endothelin (vasoconstricting) from the 
vascular endothelium.30  Impaired release of nitric oxide (NO) results in endothelial dysfunction, 
in which vessels tend to constrict and impede flow in response to stimuli that should lead to 
dilatation and flow augmentation.31 NO is an endothelial-derived vasodilator factor (EDVF) that 
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is synthesized from L-arginine by nitric oxide synthase.  Synthesis and release of NO is 
stimulated by increased blood flow (causing sheer stress on the endothelium) and circulating 
agents such as bradykinin, thrombin and acetylcholine that activate specific endothelial cell 
membrane receptors.  NO acts by increasing intracellular cGMP release in smooth muscle cells, 
resulting in decreased intracellular calcium and smooth muscle relaxation.  In addition to its role 
as an EDVF, NO may also have other antiatherogenic properties.  NO has been shown to decrease 
platelet aggregation and adhesion, limit vascular smooth muscle proliferation, inhibit monocyte 
adhesion and chemotaxis, and inhibit leukocyte adhesion to the endothelium21, 27 
Clinical assessment of endothelial function has been reported in the literature for about 
two decades, beginning with Ludmer’s study of coronary EF in the mid 1980’s.32  In this study, 
coronary angiography was used to measure the change in diameter of the coronary arteries in 
response to intracoronary infusion of the vasoactive drugs acetylcholine and nitroglycerin. In 
healthy endothelial cells, acetylcholine triggers the release of NO, resulting in vasodilation.  In an 
unhealthy endothelium, acetylcholine produces vasoconstriction via a direct effect on smooth 
muscle cells.  Endothelial-dependent vasodilation can be distinguished from endothelium-
independent vasodilation using nitroglycerin, an exogenous source of NO that acts directly on 
smooth muscle cells to facilitate dilation. 
Methods for the clinical assessment of endothelial function have evolved over the past 
few decades to include a variety of pharmacologic and physiologic stimuli as well as noninvasive 
measures of response.  A noninvasive assessment of EF in the brachial artery known as flow-
mediated dilation (FMD) was developed in the 1990’s and has become a standard assessment 
method.  Hyperemic flow is induced in the brachial artery, which subjects the endothelium to an 
increase in sheer stress, causing dilation of the vessel.  This dilation is then measured using high-
resolution ultrasound.  Brachial artery FMD has been shown to correspond strongly with invasive 
assessment of coronary EF.29, 33  The major limitations of this method are that it is subject to intra- 
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and interobserver variability and that the ultrasonography requires substantial technical 
expertise.34, 35 
According to a 2005 review of EF assessment methods,35 the two other methods used 
most commonly today are Venous Occlusion Plethysmography (VOP) and Laser Doppler 
Iontophoresis (LDI).  The VOP method measures the increase in forearm volume (following 
venous occlusion of the forearm), which represents vascular resistance, a function of normal 
endothelial function.  Vasoactive drugs can be injected locally into the brachial artery, thereby 
minimizing systemic effects.  VOP is a relatively invasive method of EF measurement but is 
nonetheless considered by some to be the gold-standard of EF measurement because of its 
superior accuracy and reproducibility.35 
In the LDI method, tiny quantities of vasoactive drugs are administered to forearm skin 
microvessels using small electric currents, and blood flow alterations (which reflect EF at the 
microvascular level) are assessed using laser Doppler imagers.  LDI is a relatively simple, 
painless, non-invasive technique that is not observer-dependent, but reports of accuracy and 
reproducibility are conflicting.  The main problem with the technique is that the applied current 
itself can cause vasodilatation independent of drug administration.35 
There is currently no consensus as to which technique is optimal, and method selection 
appears to be largely determined by experience and access to equipment.  The degree of 
correlation between measurements of endothelial function in different vascular beds has been the 
subject of several small studies, but results have thus far been inconclusive.35 The current study 
assessed endothelial function using brachial artery FMD. 
 
REVIEW OF LITERATURE: TREATMENT OF THE POSTMENOPAUSAL WOMAN 
MENOPAUSAL SYMPTOMS 
Alleviation of menopausal symptoms such as hot flashes and night sweats is the primary 
reason women seek menopausal treatment.  Vasomotor symptoms are estimated to occur in 14-
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51% of premenopausal women, 35-50% of perimenopausal women, and 30-80% of 
postmenopausal women.5  Hot flashes persist for more than a year in over 80% of cases.  
Untreated, hot flashes usually stop spontaneously within 6 years, but an estimated 9% of women 
continue to have hot flashes into their seventies.36 Treatment options include hormone therapy 
and alternatives to traditional HT, such as antidepressants, phytoestrogens, meditation, herbal 
remedies, and nutritional supplements.   
Hormone therapy 
Hormone therapy seeks to alleviate menopausal symptoms and improve pathological 
sequelae of estrogen loss by replacing the estrogen, with the ultimate goal of promoting overall 
health in postmenopausal women.  Estrogen therapy (ET) has been used in the US to manage 
menopausal symptoms since the 1940’s; and combined estrogen-progestogen therapy (EPT), 
since the 1990’s.  The role of the progestogen is endometrial protection, for unopposed ET carries 
a known risk of endometrial hyperplasia and adenocarcinoma.37  Estrogen is by far the most 
effective therapy available for the treatment of symptoms due to vasomotor instability and 
urogenital atrophy.2  A meta-analysis of 21 double-blind, randomized, placebo-controlled trials of 
oral HT demonstrated a 77% reduction in frequency of hot flashes compared to placebo, as well 
as significant reduction in symptom severity.38 Conjugated equine estrogen (CEE) and 17 beta-
estradiol (both oral and transdermal) were found to have comparable effects on the treatment of 
hot flashes.39 
Other pharmaceutical agents 
Antidepressants such as venlafaxine, paroxetine, and fluoxetine have been shown to 
improve hot flashes and are frequently employed as first-line agents in women who cannot or 
choose not to use estrogen.40  Clonidine, an alpha-2 adrenergic agonist used primarily as an anti-
hypertensive agent, is also used to treat hot flashes, both in the form of a transdermal patch and an 
oral medication.  Megestrol acetate, a progestin used primarily to treat endometrial and breast 
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cancer and as an appetite stimulant, is a highly effective treatment for hot flashes but can only be 
used for several months due to side effects such as weight gain.41 
Complementary and alternative therapies 
Women are increasingly seeking alternatives to traditional hormone therapy, including 
nutritional supplements, vitamins and minerals, herbal remedies, and meditation.  80% of women 
aged 45-60 report the use of non-prescription therapies for relief of menopausal symptoms.42  
Increasing use of complementary and alternative medicine (CAM) for menopausal symptoms is 
reflective of the growing popularity of alternative therapies for a wide variety of medical 
conditions.  Alternative therapies are defined functionally as interventions not typically available 
in US hospitals or taught in medical schools and include herbal medicine, homeopathy, vitamins, 
massage, self-help groups, relaxation techniques, and acupuncture.  The proportion of Americans 
using alternative therapies increased from 33.8% in 1990 to 42.1% in 1997, and total annual visits 
to alternative medicine practitioners were estimated to be 629 million, more than the total visits to 
all primary care physicians.43 
In spite of the paucity of data on their efficacy and long-term safety, herbal menopausal 
treatments are widely held to be safe and effective.  A survey of white, middle-aged, college-
educated women found that most respondents believe “natural” hormones are safer, cause fewer 
side effects, and are at least as effective as standard HT for symptom management.44  In a study 
of 500 women aged 40-60, 79% reported the use of botanical dietary supplements, yet only 30% 
had informed their doctor and only 3% had obtained information from healthcare professionals 
about these supplements.45 
Herbal remedies 
Herbal remedies used by American women for the management of menopausal 
symptoms include black cohosh, dong quai, chaste tree berry, evening primrose oil, ginseng, 
motherwort, red clover, and licorice.  A 2002 recent review of 10 randomized clinical trials of 
herbal therapy for primary outcome measures, including hot flashes, joint pain, fatigue, sleep 
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disturbances, and forgetfulness, reports that only black cohosh has been shown to improve 
menopausal symptoms.46 
Three out of four trials of Remifemin, a standardized formulation of black cohosh made 
by GlaxoSmithKline, show significant improvement in menopausal symptoms, especially hot 
flashes.  The active compounds and mechanism of action of black cohosh remain unknown, and 
there are no data on the safety of long-term treatment.  Of particular concern is the potential for 
estrogenic stimulation of endometrial and breast tissue.  Long-term use of alternative therapies 
such as black cohosh for relief of menopausal symptoms cannot be recommended in the absence 
of published data regarding safety, and patients must be counseled that “natural” therapies cannot 
be presumed to be without adverse effects on health.46 
Single trials of other herbs have found no significant benefit with dong quai, evening 
primrose oil, or ginseng on hot flashes.46  These few studies are of small size and short duration, 
and further investigation is necessary before any conclusions can be reached. 
Dietary phytoestrogens 
The most popular alternative to traditional HT is phytoestrogens,47 non-steroidal, plant-
derived compounds with estrogenic activity.48, 49  Phytoestrogens bind to both alpha and beta 
estrogen receptors,50 but are much weaker than endogenous estrogens, with only 1/100 to 
1/10,000 the activity.49  Phytoestrogens’ estrogenic activity was first noted in 1926 and gained 
prominence in the 1940’s with the outbreak of reproductive disturbances among sheep grazing on 
clover-rich pastures in Western Australia, dubbed “Clover disease.”51 
Phytoestrogens are divided into three main classes: isoflavones, coumestans, and lignans.  
Isoflavones are the most common types of phytoestrogens and are found most abundantly in 
legumes (soybeans, lentils, chick peas and haricot, broad, kidney, and lima beans) and in products 
containing most or all of the whole soybean (soy meal, soy grits, soy flour, tofu and soy milk). 
Soy ingredients are also added to a number of manufactured foods, and these so-called second-
generation soy foods (such as tofu yogurt and soy noodles) contain fewer isoflavones.  Of note, 
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soy sauce also has diminished isoflavone content. Lignans are found in high concentration in flax 
seed and in lesser concentration in whole grain cereals, fruits and vegetables.51  In humans, the 
two major isoflavones consumed are genistein and daidzein.  After consumption, plant 
phytoestrogens undergo enzymatic metabolic conversions in the gastrointestinal tract, yielding 
heterocyclic phenols structurally similar to estrogens.51 
Equol, a potent metabolite of daidzein, has received a fair amount of attention recently 
due to the discovery that many people are unable to make it, presumably because of differences in 
intestinal flora.  The possible existence of two subpopulations within soy trials, “equol-
producers” and  “non-equol producers,” could help explain the inconsistencies seen in the data 
with respect to isoflavones’ cardiovascular effects (described below).  Accordingly, "bacterio-
typing" individuals for their ability to make equol may prove useful in upcoming studies of the 
effects of soy isoflavones.52 
Epidemiological studies report that only 10-20% of Asian women experience hot flashes, 
compared with 70-80% of women in western countries.53-55  It has been proposed that the high 
dietary intake of isoflavones found in soy products could contribute to the decreased prevalence 
of menopausal symptoms in Asian populations.56  Average soy consumption in the US is less than 
5 g/day, compared to as much as 55 g/day in Japan.57  Among many Asian populations, dietary 
consumption of genistein alone is 20-80 mg/day, compared to 1-3 mg/day in the US.58  A cohort 
study of Japanese women found that hot flashes were significantly inversely associated with 
consumption of both total soy products and isoflavones.59 
A survey of 886 American women aged 45-65 found that 22.9% use dietary soy and that 
7.4% use it specifically for management of menopausal symptoms.60  Clinical trials have shown 
only a modest improvement in menopausal symptoms with soy products and soy isoflavone 
supplementation.61-71  A review46 of 8 randomized studies with at least 6 weeks of treatment 
showed significant relief of hot flashes in 3 of the trials.61, 67, 68  It is possible that six weeks may 
be inadequate for assessing the efficacy of vasomotor interventions, although even the longest 
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study (24 weeks) was among the studies with negative findings.62 Of note, nearly all of the 
studies showed symptom improvement in both the treatment and placebo groups, of up to 60%.46 
A 2004 review of 25 trials lasting a minimum of 4 weeks reported that phytoestrogens in 
the form of soy foods/beverages/powders, soy extracts, and red clover extracts do not relieve hot 
flashes or other menopausal symptoms.72 This review included a large randomized, double-blind, 
placebo-controlled trial of 252 symptomatic menopausal women, which found that 2 isoflavone 
supplements (Promensil and Rimostil), both extracts from red clover, did not significantly 
improve hot flashes or other symptoms of menopause relative to placebo.73  Similarly, a 2006 
American Heart Association (AHA) consensus statement states that soy protein and isoflavones 
have not been shown to improve menopausal vasomotor instability.74 
Other treatments 
In their systematic review of RCT’s of alternative treatments of menopausal symptoms, 
Kronenberg and Fugh-Berman report that vitamin E, wild yam cream and acupuncture were 
ineffective for hot flashes.  Behavioral therapies such as paced respiration (slow, deep breathing) 
have been shown to be effective in a few small studies, seem to be safe, and warrant further 
investigation.46 
  
PREVENTION OF CARDIOVASCULAR DISEASE 
Hormone therapy 
In addition to treatment of menopausal symptoms, hormone therapy has also been 
routinely prescribed over the past two to three decades for long-term prevention of cardiovascular 
disease and osteoporosis.  This practice was based on vast observational data and basic research 
findings suggesting estrogen’s protective effects on the heart and bone.  However, a series of 
large, randomized, controlled clinical trials have challenged the notion that hormone therapy is 
cardioprotective. 
Basic research findings 
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 Basic research findings and clinical trials using intermediate markers of CHD suggest a 
cardioprotective role for estrogens.75, 76  In ovariectomized monkeys, ET significantly reduces the 
development of dietary atherosclerosis.77, 78  Adams et al found coronary artery atherosclerosis to 
be reduced by approximately half in diet-induced atherosclerotic ovariectomized monkeys with 
17 beta-estradiol treatment, both with and without progesterone.79  In a subsequent study, Adams 
found that conjugated equine estrogen (CEE) treatment of coronary artery atherosclerosis led to a 
72% reduction in coronary artery plaque size.80  Plausible biological mechanisms of estrogen’s 
cardioprotective effect include benefits in lipid profile changes, antioxidant activity, coagulation, 
fibrinolysis, inflammation, and vascular reactivity. 
Lipid Profile 
Estrogen therapy has been shown in several studies, including large, randomized, 
controlled trials81 to reverse adverse changes in the lipid profile associated with menopause.  In 
these studies, oral estrogens decrease total serum cholesterol, LDL, and lipoprotein (a) 
concentrations and increase HDL and triglycerides.82-87  Transdermally delivered estrogen does 
not have the first-pass hepatic effects of oral estrogen, and therefore causes minimal to no 
increases in HDL and triglycerides.82  The addition of progestins can also diminish estrogen’s 
effect on the lipid profile, to varying degrees depending on the progestin type.81 
Antioxidant activity 
Antioxidant properties have also been attributed to estrogens.  Both short-term and long-
term administration of 17 beta-estradiol decrease the oxidation of LDL cholesterol in 
postmenopausal women,88 possibly through regulation of gene encoding enzymes responsible for 
generation and degradation of superoxide.89 
Coagulation, fibrinolysis, and inflammation 
Estrogen affects the hepatic expression of several genes involved in coagulation and 
fibrinolysis. Estrogen has been shown to increase fibrinolytic potential in postmenopausal women 
by decreasing concentrations of plasminogen-activator inhibitor type 1 (PAI-1), an 
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antifibrinolytic protein.90, 91  Estrogen demonstrates anticoagulant properties by decreasing 
fibrinogen and factor VII concentrations, but also promotes coagulation by reducing levels of 
anticoagulant proteins antithrombin III and protein S.  Hormone therapy has divergent effects on 
inflammatory markers as well: anti-inflammatory effects include reducing fibrinogen, PAI-1 and 
endothelial cell adhesion molecules concentrations, while pro-inflammatory effects include 
increasing C-reactive protein,92 matrix metalloproteinase,93 albumin, and D-dimer.94 
Vascular Reactivity: Arterial compliance 
An important component of arterial function is arterial compliance, which pertains to the 
dilation and constriction of arteries with systole and diastole.  Arterial compliance is dependent 
upon arterial wall components such as proteoglycans, elastin, and smooth muscle cells.  The 
Rotterdam Study, a population-based study, found a significant association between arterial 
stiffness and atherosclerosis.95 
Aging is associated with decreased arterial compliance.  Several studies have shown that 
estrogen enhances arterial function in post-menopausal women.96-98  Women receiving HT 
showed increased systolic arterial compliance (SAC) and decreased pulse wave velocity (PWV), 
indicating that estrogen may decrease stiffness of the aorta and large arteries in postmenopausal 
women.98 
Vascular Reactivity: Endothelium-mediated vasodilation 
Estrogen directly affects endothelial cells and has been shown to improve endothelial 
function in both non-human primates and postmenopausal women.  Estrogen receptors are found 
on endothelial cells, vascular smooth muscle cells, and adrenergic nerve endings and mediate the 
vasodilatory effect of 17-B estradiol, via synthesis of nitric oxide (NO).99 Estrogen has rapid, 
direct effects on endothelium-dependent coronary dilation: intravenous injection of ethinyl 
estradiol leads to dilation of atherosclerotic coronary arteries within 20 minutes in monkeys.100  
Replacement of estrogen enhances endothelial-dependent vasodilation in normocholesterolemic 
ovariectomized rabbits101 and in atherosclerotic ovariectomized monkeys.77 Addition of cyclic or 
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continuous medroxyprogesterone acetate (MPA) to the conjugated equine estrogen regimen 
blunts the endothelium-dependent vasodilation of CEE alone.102   
Estrogen administration in postmenopausal women induces positive effects on 
endothelial function and blood flow in normal and atherosclerotic arteries.103-107 Estrogen infusion 
acutely potentiates endothelium-dependent vasodilation of coronary arteries108 and the brachial 
artery,105 and it also attenuates abnormal coronary vasomotor responses to acetylcholine.104, 109  
Oral administration of estradiol and CEE has also been shown to improve endothelium-dependent 
flow-mediated vasodilation.106, 107 
 
Observational Studies 
Extensive observational data, from more than 40 studies, suggest that women who take 
hormone therapy have a 35-50% reduction in the risk coronary heart disease compared to non-
users.110  Particularly compelling is the Nurses’ Health Study (NHS), with its enrollment of over 
70,000 postmenopausal women, sound methodology, and twenty years of follow-up.  Results 
demonstrate a 40% reduction in CHD risk in women taking estrogen or combined estrogen-
progestogen compared with women who have never used HT.111-114  Surprisingly, no dose-
response or duration-response effects were demonstrated in the NHS.  In fact, coronary benefits 
diminished with longer duration of HT.114  Cardiovascular benefit of HT was found to be 
especially striking for secondary prevention in women with CHD, with 35-80% risk reduction.115-
117 
 
Randomized Clinical Trials  
As mentioned above, results of recent, large, randomized, placebo-controlled trials have 
challenged the use of HT for the prevention of CVD.  Data from the Heart and Estrogen/Progestin 
Replacement Study (HERS-I and –II), the Women’s Heath Initiative (WHI), other smaller 
controlled trials, and meta-analyses fail to confirm a cardioprotective role for HT.  Significant 
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confusion exists among patients and providers regarding how to apply these findings to clinical 
practice. 
Primary prevention of CVD 
The WHI included two parallel trials118, 119 designed to evaluate HT for the primary 
prevention of cardiovascular and other diseases in healthy postmenopausal women ages 50-79.  
Both arms were prospective, 8-year trials scheduled for completion in 2005. 
The combined estrogen-progestogen arm of the WHI (CC-EPT vs. placebo in over 
16,000 women) was prematurely discontinued in 2002 by the data safety monitoring board 
according to predetermined cut-offs for “hazard ratio” and “global risk” to subjects.  A hazard 
ratio is an annual calculation of risk relative to placebo, while global risk is a subjective 
risk/benefit evaluation.  The study was halted because of the invasive breast cancer hazard ratio in 
year 5.  Hazard ratios greater than 1 were also found for stroke, cardiovascular events, and 
thromboembolic events, but were below the threshold for study termination.  
The effects of the WHI CC-EPT regimen (0.625 mg/day CEE and 2.5 mg/day MPA) on 
cardiovascular risk factors were as follows: increased rate of CHD events, with greatest increase 
in year 1; increase in stroke; and increase in venous thromboembolic events.  The risk of breast 
cancer was also increased, while the risk of fracture and colorectal cancer were significantly 
decreased.118  
The unopposed estrogen arm of the WHI study (ET vs. placebo in nearly 11,000 women 
with prior hysterectomy) was terminated in early 2004 by the National Institutes of Health due to 
increased incidence of stroke and a lack of cardioprotection.  The ET regimen (0.625 mg/day 
CEE) failed to demonstrate a cardioprotective role for ET, but in contrast to the combined trial, 
did not show an increased risk of CHD.  A subgroup analysis of women 50-59 suggested a 
decreased risk of CHD, but this result was not statistically significant.  As with the combined 
arm, there was an increase in stroke and venous thromboembolism, and decrease in hip fracture.  
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No significant difference was found in the rate of colorectal cancer.  Breast cancer rates actually 
decreased with CEE use, but this finding fell just short of statistical significance (P=.06).119   
The WHI also included the Women’s Health Initiative Randomized Controlled Dietary 
Modification Trial,120 which studied the cardiovascular effects of a diet low in fat and high in 
fruits, vegetables, and grains intended to reduce cancer.  The intervention group received 
intensive behavior modification in individual and group sessions aiming to reduce total fat to 20% 
of calories and increase vegetable/fruit consumption to 5 servings/day and grains to 6 
servings/day, and the comparison group received dietary education materials.  Over a mean of 8.1 
years, the low-fat dietary intervention did not have a significant effect on CHD, stroke, or CVD in 
postmenopausal women aged 50-79 years.  The low-fat intervention did not distinguish between 
different types of fat, such as saturated and polyunsaturated and trans fats, and therefore is not a 
test of the current dietary guidelines for CVD prevention, which recommend a plant-based, high-
fiber diet high in fruits, vegetables, whole grains, nuts, legumes, fish, and low-fat dairy products 
and substitution of saturated and trans fats with mono- and polyunsaturated fats.121 
Secondary prevention of CVD 
In the HERS-I trial, 2763 postmenopausal women younger than 80 years with known 
coronary disease were randomized to CC-EPT regimen (0.625 mg/day CEE and 2.5 mg/day MPA 
or placebo.  Data revealed no significant differences between study groups in CHD events or any 
secondary cardiovascular outcomes, despite an 11% decrease in LDL levels and a 10% increase 
in HDL levels.  Within the overall null effect, a pattern of increased CHD risk in year 1 and a 
decreased risk in years 3 to 5 relative to placebo was observed.  Treatment with CC-EPT also 
significantly increased the rate of thromboembolic events and gallbladder disease.122 
HERS-II was an unblinded follow-up for 2.7 years of 93% of surviving HERS-I subjects, 
designed to investigate whether the CHD risk reduction in years 3-5 of HERS persisted with 
additional years of follow-up.  The reduction in CHD events among women taking hormones did 
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not persist; thus, after a total of 6.8 years, HT did not decrease CHD risk events among 
postmenopausal women with coronary disease.123 
The Estrogen Replacement in Atherosclerosis (ERA) trial found no benefit with either 
combination therapy or estrogen alone in women with known coronary disease.124  
A 2002 meta analysis of HT for primary prevention of CVD concludes that benefits of 
HT include prevention of osteoporotic fractures and colorectal cancer, harms include increased 
risk of CHD, thromboembolic events, stroke, cholecystitis, and breast cancer with 5 or more years 
of use, and uncertainties include dementia.125  Another meta-analysis designed to evaluate 
potential explanatory variables of the relationship between HT, CVD, and CHD confirms the 
findings of randomized trials that HT is not effective for secondary or primary prevention of 
CVD events.126 
It is important to note that the increases in CVD and breast cancer risks associated with 
the WHI CEE-MPA regimen were quite small.  The absolute excess risk of serious adverse events 
(defined as CHD, stroke, pulmonary embolism, breast cancer, hip fracture, and colorectal cancer) 
due to HT was 19 events per 10,000 women per year (or approximately 2 events per 1000 person-
years).  The absolute excess risk is presumed to be much smaller for younger women: 1 event per 
1000 person-years for 50-year-old-women, for whom estimates of disease rates are estimated to 
be about half of those of 60-year-old-women.127  In the estrogen-only arm, the absolute excess 
risk of adverse events was a non-significant 2 events per 10,000 person-years.119 
 
Interpreting the Data 
While data from clinical trials are consistent with observational data with respect to 
nearly all outcomes measured (including stroke, thromboembolic events, hip fracture, breast 
cancer and colorectal cancer), they show striking divergence with respect to CHD.128  A number 
of factors have been proposed to explain the inconsistency of CHD results, including 
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methodologic issues, differences in hormone regimens, and characteristics of the patient 
populations. 
Methodologic factors 
Methodologic factors that may have contributed to the CHD risk reduction in the 
observational studies include the “healthy user” bias (failure to adequately control for the fact that 
hormone users are generally healthier than nonusers); the compliance bias (women who adhere to 
HT tend to adhere to other health-promoting behaviors as well); and the incomplete capture of 
early events (many women enrolled in the observational trials were long-time rather than new 
hormone users).  If the observational studies were subject to confounding variables such as the 
“healthy user” and compliance biases, however, one would have expected the data for other 
diseases such as stroke, which shares many lifestyle and behavioral factors with CHD) to be 
similarly affected.128    
Hormone Regimens 
Another possible explanation for the discordant data relates to variations in hormone 
regimens from study to study, including the type of estrogen used and the addition of a 
progestogen. 
The endogenous form of estrogen in premenopausal women and the most bioavailable 
exogenous form is 17 beta-estradiol.  The formulations most commonly used by women in the 
United States, and those used in HERS and WHI trials, are conjugated equine estrogens, which 
are a mixture of estrogens derived from pregnant mares’ urine.  Results of clinical trials using 17 
beta-estradiol are mixed. 
The Estrogen in Prevention of Atherosclerosis Trial (EPAT) randomly assigned 222 
healthy postmenopausal women to either 17 beta-estradiol or placebo and found that ET 
decreased the risk of atherosclerosis, assessed by carotid artery intima-media thickness (IMT).129  
A study of 321 healthy postmenopausal women in which a progestogen (gestodene) was added to 
17-beta estradiol found no reduction in the progression of subclinical atherosclerosis by IMT.130 
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Two studies of secondary prevention using 17 beta-estradiol in women with CHD show 
no benefit relative to placebo.  Data from the oEStrogen in the Prevention of ReInfarction Trial 
(ESPRIT) indicate that unopposed estradiol valerate (17 beta-estradiol) does not reduce cardiac 
events among postmenopausal women who have survived a first myocardial infarction.131  In the 
Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial 
(WELL-HART) 17 beta-estradiol alone or with sequentially administered MPA failed to effect 
the progression of atherosclerosis among older postmenopausal women with established coronary 
artery atherosclerosis. 132 
Another factor that may influence the cardiovascular outcome of HT is the addition of a 
progestogen to the hormone regimen.  Many clinical trials have used CC-EPT regimens, while the 
majority of women in observational studies were treated with estrogen alone.  It is believed that 
some formulations of progestogens may mitigate the beneficial effects of estrogen on 
cardiovascular health, but there is currently no consensus regarding the recommended 
progestogen regimen.37  The WHI results, in which elevated risk of CHD was seen in the 
combined trial but not in the unopposed trial, are supportive of a blunting effect for 
progestogens.133  
 A study in rats used a fluorescent imaging technique to examine acute peripheral and 
cerebrovascular responses to progesterone, synthetic progestins (MPA and norethindrone), and 
estrogens (CEE and 17 beta-estradiol), and found that synthetic progestins, but not progesterones 
or estrogens cause rapid vascular toxicity.  The toxic effects included endothelial disruption, 
margination and adherence of leukocytes and platelets to vessel walls, platelet aggregation, and 
formation of large and small thrombi, all of which are early events in atherogenesis.134 
Patient populations 
Other possible explanations for the discordance between observational and clinical 
studies pertain to characteristics of the patient populations in each--namely, body weight, age, and 
the number of years since menopause.  The mean BMI in the Nurses’ Health Study was 24.3,128 
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while those in the WHI trials were 28.5 and 30.1.118, 119  A large cohort study of almost 300,00 
women found that the correlation between HT use and decreased CHD risk was most pronounced 
in women whose BMI was less than 22.135  
In the observational studies, nearly all women were less than 55 years old and were 
taking hormones for menopausal symptoms.  In the Nurses’ Health Study, for example, the age 
range was 30-55, and 80% were less than 2 years postmenopausal.128  By contrast, the average 
ages of the women in the ERA, HERS and WHI trials were 65, 67 and 63, respectively,118, 119, 122, 
124 and only about 10% of the women in the WHI were symptomatic.136   Women in the CC-EPT 
arm of the WHI were an average of 12 years post-menopausal; the average number of years post-
hysterectomy was not provided in the publication of the unopposed arm.  A power analysis of the 
CC-EPT arm reveals that the study was 10-fold underpowered to detect cardioprotection of HT 
administered during the menopausal transition of the magnitude demonstrated by the Nurses’ 
Health Study.137   
Differences in CHD outcomes between early- and late-start HT are likely related to the 
extent of underlying atherosclerosis.  The progression of atherosclerosis in women is such that 
active formation of coronary artery lesions occurs between the ages of 45 and 55, and clinical 
complications from these lesions develop on average by the age of 65.128  Animal studies suggest 
that estrogen may have favorable effects in the early stages of atherosclerosis but little to no 
impact on complicated plaques and coronary events.76  Studies of cynomolgus monkeys show that 
those with minimal atherosclerosis showed 70% inhibition of coronary artery atherosclerosis with 
CEE treatment compared to placebo;80, 138 those with moderate atherosclerosis, only 50%; and 
those with a substantial delay in initiation of treatment (comparable to 6 human years) and 
therefore advanced atherosclerosis, showed no effect on the extensiveness of disease.139 
Because the patient populations in WHI and HERS were significantly older and further 
from menopause than those in epidemiologic studies, the data cannot be generalized to younger 
women initiating HT during the menopausal transition for management of menopausal symptoms.  
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In order to test the hypothesis that early initiation of hormone therapy, in newly menopausal 
women, confers a cardioprotective effect, a new study of HT in younger women closer to 
menopause is underway.140  KEEPS is a primary prevention trial that will examine the effect of 
CEE and transdermal estradiol, both with cyclic oral, micronized progesterone, on two 
intermediate markers of CHD--carotid intimal medial thickness and coronary calcium--in women 
who are between the ages of 42-58 and within 36 months of their FMP.  
Changes in clinical practice in response to the WHI 
In response to the WHI, the USFDA has mandated that all estrogen products carry a 
warning of the risk of cardiovascular disease and cancer.141  The US Preventive Services Task 
Force, American College of Obstetricians and Gynecologists, American Heart Association, North 
American Menopause Society, and Canadian Task Force on Preventive Health Care have all 
issued statements recommending against the use of HT for the prevention of chronic diseases in 
postmenopausal women.  The general guiding principle of most professional organizations is that 
HT be prescribed at the lowest dose and for the shortest duration possible in consideration of the 
treatment goals of the individual woman.  
The International Menopause Society takes a different view of the matter by arguing that 
the clinical trials to date do not answer the question whether HT initiated during the menopausal 
transition is effective for primary prevention of CVD.  The IMS therefore recommends 
“continuation of the presently accepted global practice, including the use of estrogen + progestin, 
or estrogen alone in the case of women who have undergone hysterectomy, for the relief 
menopausal and urogenital symptoms, avoidance of bone-wasting and fractures, and atrophy of 
connective tissue and epithelia.”136 
In the year following the WHI publication in July 2002, prescriptions for hormone 
therapy dropped by 38% overall, and by 74% for Prempro in particular (the CEE-MPA drug used 
in the combined trial).142  The percentage of postmenopausal women taking HT had increased 
from 33% to 42% between 1995 and 2001, but fell to 28% by July 2003.143  
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SERMs 
Due in large part to the findings of HERS and WHI, women are increasingly seeking 
alternatives to traditional HT, including SERMS and phytoestrogens.  As the name suggests, 
selective estrogen receptor modulators bind with great affinity to estrogen receptors and have 
agonist effects on particular tissues and antagonist effects on others.    
Raloxifene is a SERM that has activity in bone and other systems, but not in reproductive 
tissue.  The Multiple Outcomes of Raloxifene Evaluation (MORE) trial examined 7705 
osteoporotic women younger than 81 who were randomly treated with either raloxifene or 
placebo.  Treatment with raloxifene resulted in a 90% decrease in the risk of estrogen receptor 
(ER)-positive breast cancer, as well as a decrease in vertebral fracture and an increase in bone 
mineral density in the spine and femoral neck.  Raloxifene did not increase the risk of 
endometrial cancer, but it did increase the risk of thromboembolic disease and hot flashes.144, 145 
Raloxifene’s effect on CVD is unclear, and is the subject of the RUTH trial (Raloxifene 
Use for The Heart), an ongoing study of over 10,000 postmenopausal women at risk of CHD.146 
Secondary analysis of the MORE data showed no effect on CVD risk overall, but decreased risk 
of CVD events in women with elevated CVD risks.147 
Studies of intermediary markers of CVD show that raloxifene reduces serum LDL, 
homocysteine, lipoprotein (a), and plasma fibrinogen but has no effect on HDL, triglycerides, 
CRP, or plasminogen-activator inhibitor concentrations.148-151 Raloxifene has been shown to 
enhance endothelial function in postmenopausal women relative to both placebo152 and HT.153 
Tamoxifen is a SERM used primarily for treatment or prevention of ER-positive breast 
cancer.  Like raloxifene, it has been shown to have beneficial effects on osteoporosis and 
intermediate markers of CVD, and adverse effects on thromboembolic disease and hot flashes.  
Unlike raloxifene, however, tamoxifen causes endometrial hyperplasia and endometrial cancer, 
and its clinical use is therefore limited to treatment and prevention of breast cancer.154 
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Soy Isoflavones 
Epidemiological studies indicate that increased phytoestrogen consumption in Asian 
countries and in vegetarians may be associated with a lower incidence of cardiovascular disease 
and breast and prostate cancer.51, 57, 155  Experimental data are also supportive of a 
cardioprotective role for phytoestrogens.  
A significant body of evidence suggests that soy protein in place of animal protein 
(casein) decreases progression of atherosclerosis.  Anthony et al randomized monkeys to diets 
containing casein protein, soy protein with isoflavones extracted (SPI-), or soy protein with 
isoflavones intact (SPI+).  They found the worst coronary artery atherosclerosis in the casein 
group, intermediate disease in the SPI- group, and least in the SPI+ group, with ~85% and ~50% 
reduction compared to casein and SPI- groups, respectively.156  A subsequent trial in monkeys 
showed significant and comparable reduction in carotid artery stenosis with both soy 
phytoestrogens and conjugated equine estrogens, but not with phytoestrogen-depleted soy 
protein.138  Possible mechanisms of soy isoflavones’ antiatherosclerotic effects include alteration 
of lipid profile, antioxidant properties, antithrombotic and anti-inflammatory effects, 
antiproliferative and antimigratory effects on smooth muscle cells, and promotion of normal 
vasoreactivity.157  
Lipids 
A substantial body of evidence in both animals in humans,158-161 as well as a meta-
analysis of 38 trials,162 initially indicated a lipid-lowering role for soy protein, which led to the 
1999 approval by the USFDA of a health claim that "25 g of soy protein a day, as part of a diet 
low in saturated fat and cholesterol, may reduce the risk of heart disease."163 Recent studies of soy 
isoflavones’ impact on lipid levels have been inconsistent, however, and have generated 
controversy regarding the appropriateness of the health claim.164  These findings will be discussed 
in greater detail in the Discussions section.   
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Antioxidant effects 
Multiple clinical studies have demonstrated an association between the consumption of 
soy protein and reduction of LDL oxidation.165-169  In three studies of soy isoflavone extracts 
(without soy protein), no resistance to  LDL oxidation was seen.170-172  
Antiproliferative and antimigratory effects 
The proliferation and migration of smooth muscle cells is an integral part of the 
formation and progression of atherosclerosis.  Several studies have demonstrated soy isoflavones’ 
ability to inhibit smooth muscle cell proliferation and migration in vitro.173-175 Genistein in 
particular has been shown to inhibit DNA synthesis, extracellular matrix synthesis, and migration 
of smooth muscle cells via its interactions with the beta estrogen receptor.173 
  Coagulation, fibrinolysis and inflammation 
A study of the effects of phytoestrogens on the hemostatic system found no evidence of 
biologically significant estrogenic effects on fibrinolysis or the coagulation cascade. No 
significant changes in levels of D-dimer, vWF, PAI-1, or soluble fibrin were found.176  Genistein 
was found in one study to inhibit thrombin formation and platelet activation in vitro. 177  
Vascular Reactivity: Arterial compliance 
Soy isoflavones also have favorable effects on another important cardiovascular risk 
factor, arterial compliance.  Nestel reported that isoflavones, from both soy and red clover, 
significantly improve systemic arterial compliance, but not blood pressure or lipid profile, in 
menopausal and perimenopausal women.171, 178 
Vascular Reactivity: Endothelial function 
The effect of soy protein isoflavones on endothelial function in postmenopausal women 
is the subject of the current study.  Soy isoflavones have been shown to influence endothelial 
function positively in primates,159 but studies in postmenopausal women have produced 
conflicting results. Four studies reported a significant increase in flow-mediated vasodilation of 
the brachial artery with isoflavone treatment,179-182 while six studies reported no effect on 
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endothelial function. 183-188  Further study is warranted to elucidate the effects of soy isoflavone 
protein on endothelial function in postmenopausal women.  
Lecithin, a phosphatidylcholine-containing compound, has been shown to lower 
cholesterol in hyperlipidemic animals189-192 and humans,193 but not in normolipidemic animals and 
humans. 193, 194 Choline is a component of lecithin and is a precursor to acetylcholine, which leads 
to vasodilation in healthy endothelium and vasoconstriction in unhealthy endothelium.32  To our 
knowledge, soy lecithin’s effect on endothelial function has not been studied. 
 
STATEMENT OF PURPOSE 
Fear of adverse effects of hormone therapy and the perception that alternative therapies 
are safer than HT have influenced many women to pursue alternatives to conventional hormone 
therapy.  More and more women are consuming soy products and supplements, yet the effects of 
soy isoflavone protein on endothelial function and overall cardiac risk in postmenopausal women 
are poorly delineated.44, 46, 60  Reliable information about the benefits and risks of soy isoflavone 
protein is needed in order for women and their health care providers to make informed decisions 
about menopausal health.  Management of menopausal symptoms and prevention of 
cardiovascular disease and osteoporosis in perimenopausal women are matters of great public 
health significance and warrant further clinical investigation.  We therefore conducted a 
randomized, double-blind, placebo controlled crossover trial of soy isoflavone protein and soy 
lecithin products on endothelial function in healthy postmenopausal women.  Endothelial 
function, measured as flow-mediated dilation of the brachial artery, is the primary outcome 
measure.  Other measures include lipid panel. 
We hypothesize that soy isoflavone and soy lecithin will improve endothelial function, as 
measured by brachial artery flow-mediated dilation.  With respect to isoflavones, we base this 
hypothesis on isoflavones’ demonstrated favorable effects on vascular reactivity in non-human 
primates, as well as on estrogen’s improvement of endothelial function in both animal and human 
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models, coupled with the knowledge that phytoestrogens are structurally similar to estrogens and 
have activity at alpha and beta estrogen receptors.  Soy lecithin’s effect on endothelial function 
has not been studied to date, but as a source of choline and therefore acetylcholine, lecithin could 
be expected to increase endothelial-dependent vasodilation. 
 
MATERIALS AND METHODS 
Subjects  
Healthy postmenopausal women were recruited from the general population of 
Southwestern Connecticut (CT), primarily through mass media (newspaper advertisements, press 
releases) and posters.  A subject flow diagram is provided in Figure 1.  Those subjects (n = 89) 
who responded to recruitment efforts were prescreened using a semi-structured telephone 
interview.  Inclusion criteria were healthy, postmenopausal (defined as absence of menses for at 
least one year, FSH>40 miu/ml, and estradiol<25 pg/ml) women not currently using hormone 
replacement, who were normotensive (<140/90) and normolipidemic by laboratory assay (total 
cholesterol < 240).  Exclusion criteria were smoking, history of cardiovascular disease, breast or 
endometrial cancer, vasoactive medication use, daily prescription drug use, regular use of high 
dose vitamin C>250 mg, vitamin E>400iu or fiber supplements, and failure to meet inclusion 
criteria or anticipated inability to complete the study protocol. 
Subjects who met initial prescreening criteria (n = 33) underwent a clinical screening 
examination  (height, weight, body mass index [BMI] and blood pressure measurements) and 
laboratory testing (fasting cholesterol, HDL, LDL, triglyceride levels, estradiol, FSH, 
choline/phosphatidylcholine and isoflavone).  Subjects provided written informed consent prior to 
performing screening and study procedures. The study was approved by the Institutional Review 
Board of Griffin Hospital, Derby, CT. 
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Study protocol 
Subject management 
After meeting eligibility criteria, twenty-five subjects underwent a baseline ultrasound 
scan and were randomly assigned to treatment groups by the data manager using block 
randomization.  Subjects were randomly assigned to a sequence of 4 sustained treatment phases, 
each 28 days (4 weeks) in duration with a 28 day (4 weeks) wash-out in-between.  Treatment 
products were consumed twice daily (in the form of packets of powder and packets of granules) 
and included: soy isoflavone protein (SP, 25g/day) and soy lecithin (SL, 20g/day); soy isoflavone 
protein (25g/day) and placebo lecithin (PL); placebo protein (PP) and soy lecithin (20g/day); and 
double placebo.  
Subjects were instructed throughout the study to consume one package of powder (mixed 
with water to create a beverage shake, chocolate and vanilla flavored) and one package of 
granules twice a day.  Treatments were taken in the morning and then later in the day.  Patients 
were instructed to consume any missed treatments as soon as they remembered, unless it was time 
for the next treatment, in which case they were instructed to return the unused doses at the next 
scan.   
On the last day of each treatment period, following an overnight fast (nothing to eat or 
drink after midnight) and timed to precede the scheduled scan time by 2 hours, subjects ingested 
(at home) the final morning treatment dose with water only, and then reported to the PRC for 
compliance adherence review, endothelial function testing, and phlebotomy. 
Compliance Adherence Review 
All participants were contacted by telephone every two to four weeks and two days prior 
to the end of each treatment phase to monitor compliance, inquire about any study related issues, 
significant side effects, reinforce compliance, serve as a reminder for A.M. previsit testing 
instructions, and answer potential questions.  At each visit, adherence to A.M. pretesting 
instructions were verified with the subjects before each scan. Subjects returned any unused 
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treatment product, which was used to corroborate self-reported compliance. Compliance was 
defined as >80% use of treatment.   
Brachial Artery Reactivity Studies (BARS) methodology 
The brachial artery reactivity studies (BARS) methodology is comparable to those of 
other leading labs, as described in “Guidelines for ultrasound assessment of endothelial-
dependent flow–mediated vasodilation of the brachial artery,”34 enhanced by the use of software 
(Brachial Analysis Tools, Medical Imaging Applications) to automate the brachial artery diameter 
measures. The BARS procedure is designed to measure flow-mediated dilatation in the brachial 
artery as a percent of resting vessel diameter.34  Our methods have been published previously.195  
In brief, brachial artery reactivity was evaluated at baseline (week 0) and after each treatment 
(weeks 4, 12, 20, 28).  Endothelial function was measured non-invasively in the right brachial 
artery by means of a high frequency ultrasound machine (Philips Medical Systems: Sonos 4500, 
Andover, MA) in accordance with published guidelines.34 Subjects were required to lie at rest in a 
quiet, temperature-controlled, softly lit room for at least 15 minutes before scanning was initiated.  
Subject comfort was enhanced with the addition of an angled knee cushion, which relieved back 
strain.   
To create a flow stimulus in the brachial artery, a sphygmomanometer cuff is placed on 
the upper arm proximal to the transducer.  The reference diameter of the brachial artery was 
measured from two-dimensional ultrasound images using a high frequency, 10-15 MHz, vascular 
ultrasound transducer (Philips Medical Systems, 15-6L L7540 linear array transducer, Andover, 
MA).  The brachial artery was imaged at a location 3-7 cm above the antecubital fossa in the 
longitudinal plane.  A segment with clear anterior and posterior intimal interfaces between the 
lumen and vessel wall was selected for continuous 2D gray scale imaging.  The transmit (focus) 
zone was set to the depth of the near wall because of difficulty in differentiating the near from the 
far wall “m” line (the interface between media and adventitia).  Diameter measurements were 
taken from the anterior to the posterior “m” line, over a consistent segment of vessel at least 10-
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15 mm in length in diastole.  Arterial flow-velocity was measured by means of a pulsed Doppler 
signal at a 70° angle to the vessel, with the range gate in the center of the artery.  Flow was 
determined automatically by multiplying the arterial cross-sectional area (πr2) by the Doppler 
flow velocity.  A reference blood flow and diameter are recorded.  Arterial occlusion is created by 
cuff inflation to 50 mmHg above the systolic blood pressure.  The cuff is inflated for 5 minutes. 
This causes ischemia and consequent dilation of downstream resistance vessels via autoregulatory 
mechanisms.34 Cuff deflation induces a brief high-flow state through the brachial artery (reactive 
hyperemia) to accommodate the dilated resistance vessels.  The resulting increase in shear stress 
causes the brachial artery to dilate.  A pulsed Doppler signal is obtained within 15 seconds of cuff 
release to assess hyperemic velocity, and a longitudinal image of the artery is recorded 
continuously from 20 seconds to 2 minutes after cuff deflation. 
The timing of each image frame with respect to the cardiac cycle was determined with 
simultaneous ECG gating during image acquisition via the high-quality mainframe ultrasound 
system.    Images were acquired on videotape and magnetic optical disk for evaluation and 
analysis.  All BARS were completed prior to 12 noon.  
Handling of BARS Images and Data 
Measures of vessel diameter and flow velocity were generated after each scanning 
session.  Velocity measures were generated automatically using the pulsed wave Doppler.  
Diameter measurements were obtained by automatic identification using edge-detection software 
(Brachial Analysis Tools, Medical Imaging Applications 2001,Iowa City, IA), an automated 
method for near and far wall detection and vessel diameter measurements in brachial ultrasound 
image sequences. 196  The method automatically learns properties for the analyzed vessel in one 
frame of a sequence that is analyzed under training parameters.  The vessel properties were 
reflected in the cost function used in a graph-search-based border detection process.  This 
automated method decreased variability by generating an average diameter measurement derived 
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from multiple measures obtained along a segment of the vessel.  Several automated quality 
control steps are incorporated to improve accuracy and reproducibility.  These computerized 
readings are charted on a standardized scan form, which and scanned into the database for 
analysis. Measurement of vessel diameter and flow velocity was conducted by a dedicated 
vascular research specialist who was blinded to treatment assignment. A random sample of 30 
BARS was provided to the clinical research specialist for a blinded second reading.  The resultant 
coefficient of intra-observer reliability was 0.98; P<.0001. 
Serum assays and analysis  
Venous whole blood was drawn from each subject for serum assays for lipids, 
choline/phosphatidylcholine, and isoflavones (Equol, Daidzein, Dihydrodaidzein, O-
desmethylangolensin, genistein), which were assessed at baseline and following each treatment 
period.  Serum for choline and phosphatidylcholine analysis was sent to the University of North 
Carolina, and serum for isoflavone analysis was sent to the University of Alabama (Dr. S. 
Barnes). 
Adverse effects 
An adverse effects questionnaire was administered at the end of each treatment 
assignment to compare side effects of soy lecithin, soy isoflavone protein, and placebo.   
 
Statistical analysis 
Statistical analysis was performed by Dr. Valentine Njike.  The sample size was 
determined to allow for approximately 10% attrition and noncompliance rate and provide at least 
80% power to detect a minimal difference of 3.5% in FMD between isoflavone and placebo.  
Data were analyzed using SAS software (Version 8.2 of the SAS System for Windows; SAS 
Institute Inc., Cary, NC). Endothelial function was assessed as flow-mediated dilation; this was 
calculated as the percent change in diameter post-occlusion of brachial artery at 60 seconds relative 
to the measurement at baseline before cuff inflation. To account for variability in the strength of the 
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stimulus that triggered endothelial reactivity (i.e., hyperemic flow), FMD was divided by flow at 
15 seconds post-cuff deflation to create a stimulus-adjusted response measure (SARM).195 Other 
measures include plasma analytes. 
   Paired t-testing was performed to assess change in FMD, SARM, serum measures, and 
blood pressure from baseline. The paired t-test was also used to compare baseline measures of 
FMD, SARM and serum measures to the values obtained at the end of each washout period to 
demonstrate complete washout. To adjust for any potential carryover effect following washout, 
treatment sequence (timing of each treatment) was entered as a control variable in multivariable 
analysis.  The change in FMD, SARM and serum measures between the treatment groups was 
assessed using repeated measures ANOVA. The combined effects of independent variables and 
treatment assignment on endothelial function were assessed with multivariable models using 
ANCOVA.  A two-tailed alpha of less than 0.05 was considered statistically significant. 
 
Role of student 
As a student researcher, I participated in the planning of the study, the recruitment and 
selection of study subjects, including telephone prescreenings, review of literature relevant to the 
study, and drafting of the abstract and manuscript for publication.  From June through August of 
2002, I worked ~40 hours per week at the study site, the Yale Prevention Research Center, during 
the subject recruitment phase of the study.  Although I was not able to be physically on-site 
during the implementation of the study, I remained in contact with the study team throughout.  
During the winter of 2003, I took two weeks away from clinical rotations to research and write 
drafts of this thesis, as well as the study manuscript for publication.  I took an additional two-
week block of research time in early 2006 to update the literature review and complete this thesis 
project. 
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RESULTS 
Subjects 
Subjects ranged in age from 46 to 76.  Mean age was 61.5 years, BMI was 26.34 kg/m2, 
and the mean time from menopause was 118.91 months.  Demographic data for the study 
population are provided in Table 1.  A total of 22 of 25 eligible, recruited, and randomized 
participants completed the study.  Two women withdrew from the study due to incompatibility 
with treatment (dietary preferences, and menopausal symptoms); one woman withdrew for 
reasons unrelated to the study. 
Brachial artery flow-mediated vasodilation  
Table 2 provides a summary of the results of the vascular reactivity studies. The mean 
baseline FMD (pre-treatment FMD) was 8.60 + 7.20.  FMD did not change significantly (P > 
0.05) from baseline with any of the 4 treatments.  No statistically significant (P > 0.05) difference 
was seen in FMD between treatment assignments. A trend was suggested, however, with FMD 
highest after treatment with both soy protein and lecithin (7.50 + 9.85), followed by soy protein 
and placebo lecithin  (5.51 + 10.11), placebo protein and soy lecithin (5.35 + 6.13), and lowest 
after double placebo (4.53 + 7.84). Our results persist after controlling for respondent 
characteristics. A similar trend was observed with SARM. 
Lipid Panel 
Total cholesterol and LDL decreased significantly (p <.001) from baseline after all four 
treatments (see Table 2).  The between-treatment cholesterol reductions did not differ 
significantly (p>0.05). Treatment with both soy isoflavone protein plus soy lecithin significantly 
(p < 0.05) increased HDL relative to double placebo. Soy isoflavone protein and soy lecithin 
significantly (P < 0.05) increased HDL/LDL relative to baseline value (soy isoflavone protein 
and soy lecithin, 0.64 ± 0.19; soy isoflavone protein and placebo lecithin, 0.58 ± 0.17; placebo 
protein and soy lecithin, 0.65 ± 0.18; double placebo protein, 0.55 ± 0.15; baseline,  0.49 ± 0.15). 
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Serum Choline 
Betaine levels increased significantly after treatment with soy isoflavone protein plus soy 
lecithin and soy lecithin (98.94 ± 29.63 nmol/ml, p<.0001; 92.06 ± 28.00 nmol/ml, p<.0001 
respectively) relative to baseline (40.57 ± 8.86 nmol/ml). Betaine levels also increased 
significantly relative to placebo with soy isoflavone protein plus soy lecithin and soy lecithin 
(p<0.05).  Betaine levels decreased significantly relative to baseline value in the placebo (33.27 ± 
11.19nmol/ml; p=0.0023). Choline levels increased significantly with soy isoflavone protein plus 
soy lecithin (24.31 ± 8.92 nmol/ml; p<.0001) and soy lecithin (16.07± 5.27nmol/ml; p<.0001) 
relative to baseline. No treatment assignment provided any meaningful change of 
phosphatidylcholine levels. 
Serum Isoflavone 
Baseline total serum isoflavone (pre-treatment total serum isoflavone) was 76.31 ± 
108.58 microM. After treatment with soy protein plus soy lecithin and soy protein, total serum 
isoflavone increased significantly (p<.0001) to 1586.83 ± 1045.91 microM and 1604.58 ± 887.34 
microM respectively. These increases observed differed significantly (p<.0001) compared to soy 
lecithin (118.88 ± 157.62 microM) and placebo (109.10 ± 244.18 microM). Soy lecithin and 
placebo treatment increased total serum isoflavone non-significantly (p>0.05) from baseline (see 
Table 2). 
Adverse effects questionnaire 
A side effects questionnaire administered following each treatment phase is summarized 
in Table 3.  The most common side effects reported were weight gain and headache.  Hot flashes 
were the most commonly reported menopausal symptom pre-treatment. 
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DISCUSSION  
In this study of 22 healthy postmenopausal women, soy isoflavone protein and soy 
lecithin significantly improved the lipid profile. Soy lecithin, both with and without soy 
isoflavone protein, also significantly increased serum choline and betaine levels.  
Neither soy isoflavone protein nor soy lecithin significantly improved endothelial 
function.  However, this study does suggest a favorable trend for soy isoflavone protein and soy 
lecithin with respect to endothelial function.  While not statistically significant, FMD was highest 
following treatment with both soy protein and lecithin, lower for each treatment alone, and lowest 
for double placebo. 
In animal models, phytoestrogens have been found to favorably influence vascular 
reactivity.159, 197   Honore found that soy isoflavones enhance vascular function in atherosclerotic 
coronary arteries of premenopausal monkeys. In response to acetylcholine, arteries from females 
with the low-isoflavone diet (and also from all males, regardless of diet) constricted, whereas 
arteries from females with the high-isoflavone diet dilated.  Furthermore, genistein administered 
intravenously produced dilation in the formerly constricting females on low-isoflavone diet.159  
Williams et al found a statistically significant interaction between the vasodilatory effects of 
estradiol and soy consumption.  Among surgically postmenopausal monkeys with very low 
plasma estradiol levels whose coronary arteries constricted in response to acetylcholine, those 
who received estradiol and soy isoflavones dilated more than those given only the dose of 
estradiol.198  
In a study of healthy human subjects, genistein injected into the brachial artery resulted in 
acute NO-dependent vasodilation of the brachial artery, with potency similar to 17 beta-estradiol.  
Plasma concentrations of isoflavones were much higher than in other studies with soy 
supplements.199 
The literature on soy isoflavone protein’s effect on endothelial function in post-
menopausal women is mixed.  Simons et al found no significant effect of 8 weeks of treatment 
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with 80 mg/day isoflavones in women with evidence of endothelial dysfunction.185  Three recent 
studies in postmenopausal women with hypercholesterolemia are discrepant: in one study, 
treatment with 40 g/day of isolated soy protein containing 80 mg isoflavones for 4 weeks 
improved flow-mediated vasodilation independent of lipoprotein changes,181 while two others 
showed no benefit: treatment with 25 g/day of soy protein containing 85 mg isoflavones for 6 
weeks yielded no improvement in endothelial function in one,200 nor did 6 weeks of treatment 
with 90mg/day of isoflavones.187 
Studies in healthy postmenopausal women with neither high cholesterol nor endothelial 
dysfunction are also contradictory.  Teede et al found that 3 months of treatment with 40g/day 
soy protein containing 118 mg isoflavones did not improve vascular function.186 Hale et al 
reported that 2 weeks of 80 mg/day isoflavone in the form of soy tablets failed to affect vascular 
reactivity or lipids.184  A large study of over 200 women used 99 mg/day isoflavones for a 
relatively long duration of 12 months, and also failed to find a beneficial effect on endothelial 
function.188  
On the other hand, three studies in healthy postmenopausal women do show 
improvement in endothelial function.  Steinberg et al found that treatment with 25 g/day of soy 
protein containing 107 mg isoflavones for 6 weeks favorably effects endothelial function, 
independently of lipid and antioxidant effects.180  Squadrito et al found that one year of genistein 
therapy (54 mg genistein/day) improves endothelial-dependent flow-mediated vasodilation to the 
same extent as does estrogen/progestin therapy.179  Squadrito also reported an increased ratio of 
NO to endothelin-1 with genistein therapy, suggesting that the endothelial effect is due to NO 
release.201  Colacurci et al tested the effects of both long duration (6 months) and high dose 
isoflavone treatment (60 mg/day each of both genistein and daidzein), a dose chosen to be 
between consumption in the Pacific Rim (25-45 mg/day) and in some regions of Japan 
(200mg/day).  This isoflavone regimen enhanced endothelium-dependent brachial reactivity, and 
also reduced plasma adhesion molecule levels, but not coagulation parameters.182  Contributory 
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factors to the varied outcomes of these studies include the dosage and duration of treatment, the 
type of product used (soy protein, isoflavone extract, isolated genistein or daidzein) and the 
presence of underlying endothelial dysfunction or hypercholesterolemia. 
As previously mentioned, soy protein’s role in lipid-lowering has recently been called 
into question.  The 1995 meta-analysis by Anderson et al162 of 38 controlled clinical trials 
examining the relation between soy protein consumption (averaging 47 g/day) and serum lipid 
concentrations demonstrated significant reductions, when compared to control diets, in total 
cholesterol (9.3%), LDL cholesterol (12.9%), and triglycerides (10.5%).  HDL cholesterol levels 
increased by 2.4%, but this increase was not significant.  Despite the wide range in amount of soy 
protein consumed (18-124 g/day), no dose-response effect was evident.  Rather, response to soy 
protein was found to be directly proportional to the extent of initial hypercholesterolemia,  with 
20% reductions in blood cholesterol seen in severe hyperlipidemia, down to no significant 
reductions in subjects with initial cholesterol levels <255 mg/dl.  The literature suggesting a role 
for soy protein in the treatment of hypercholesterolemia contributed to the aforementioned FDA 
approval for a health claim for food products containing at least 6.25 g of soy protein per 
serving.163  
More recent, well-controlled trials have not consistently reported substantial lipid-
lowering effects of soy protein and soy-derived isoflavones.  The 2006 AHA Science Advisory 
on soy and CVD74 reviewed 22 randomized trials of isolated soy proteins with intact isoflavones 
and found that LDL levels decreased by an average of 3% relative to control (milk or other 
proteins), with no dose-response effect.  This decrease is especially modest considering the high 
intake of soy protein consumed in the trials, averaging 50 g/day, or about half the typical total 
daily protein consumption.  Although some studies found greater lipid-lowering effects in 
hyperlipidemic subjects compared to normolipidemic subjects,202, 203 no overall relation across the 
22 trials was seen between initial cholesterol levels and lipid lowering response.  No significant 
effects on HDL, triglycerides, or lipoprotein (a) were found.      
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Whether soy’s proposed hypocholesterolemic effect is attributable to isoflavones has 
been the subject of much debate.  The 2006 AHA Advisory74 looked at 19 trials that studied the 
lipid-lowering effects of soy protein with varying quantities of isoflavones and of isoflavone 
supplements in pill form compared to placebo.  The overall effect of soy isoflavones on LDL 
levels was found to be nil (0%).  3 of the 19 studies found a significant link between isoflavone 
content and decreased LDL levcls,204-206and 3 reported significant decreases in total 
cholesterol.202-204  The AHA consensus statement is consistent with a 2003 meta-analysis 
concluding that changes in isoflavones are unrelated to changes in LDL and HDL levels.207  In the 
current study, soy protein with intact isoflavones significantly decreased total and LDL 
cholesterol relative to baseline, but not relative to placebo protein.  This result would have been 
considered a negative finding by the AHA Science Advisory criteria, but is nonetheless consistent 
with substantial prior evidence that soy protein with intact isoflavones has a lipid-lowering effect 
in postmenopausal women. 
 Favorable effects of soy supplementation on metabolic control in diabetes were reported 
by Jayagopal et al.208   In a randomized, double-blind, cross-over study of 32 postmenopausal 
women with type 2 diabetes, fasting insulin and HbA1c levels improved, along with serum lipids, 
following 12 weeks of supplementation with soy protein (30 g/day containing 132 mg/d 
isoflavones).  Thus, despite the neutral effects of soy observed in the current study, the possibility 
of cardioprotective effects, at least in certain population sub-groups, still exists. 
 Soy lecithin has previously been shown to improve the lipid profile in hyperlipidemic 
patients, but not in normolipidemic patients.193  In the current study among normolipidemic 
women consuming 20g of soy lecithin per day, SL significantly lowered LDL cholesterol relative 
to baseline and to soy isoflavone protein, but not relative to placebo. The mechanism of lecithin’s 
lipid-lowering effects remains unknown.   In this study, soy lecithin also significantly increased 
levels of choline and betaine. To the best of our knowledge, the effects of lecithin on endothelial 
function have not previously been studied.  Despite the increase in plasma choline levels, which 
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could be expected to increase endothelial-dependent vasodilation via acetylcholine, the current 
study failed to demonstrate a significant effect of lecithin on endothelial function. 
 This study suggests a favorable trend in FMD with soy isoflavone protein and soy 
lecithin supplementation relative to placebo, but a significant effect on endothelial function could 
not be confirmed.  These findings may be due to study limitations such as small sample size, 
timing of testing, dose, delivery vehicle, and subject characteristics.   
There exists the possibility of a Type II error due to small sample size and limited 
statistical power. The study was only powered to detect a 3.5% change in FMD, based on 
previous findings by our group with SERMs.152  The variability of FMD was unexpectedly high, 
such that the standard deviation was greater than the mean FMD values. Other investigators have 
noted increased %FMD variability with upper arm cuff placement relative to lower arm 
placement.209  
 It is noteworthy that FMD was lower after all treatments, including double placebo, than 
at untreated baseline.  One possible explanation for the decline in FMD from baseline relates to 
the timing of the testing and the delivery vehicle.  The baseline BARS testing was conducted 
following an overnight fast, but for each of the post-treatment scans, study subjects consumed the 
AM dose of the treatment two hours prior to the scan (after an overnight fast).  Furthermore, the 
shakes provided to subjects in both treatment and placebo phases had a high glucose content, and 
hyperglycemia has been shown to inhibit endothelium-dependent coronary vasodilation through 
oxidative stress.210-212 It is likely that acute glucose loading prior to the post-treatment scans 
compromised endothelial function, possibly masking any potential beneficial effects of soy 
isoflavone protein and soy lecithin. 
 FMD at baseline was surprisingly robust and could have made it difficult to perceive 
a favorable effect of soy on EF.  The baseline FMD in the current study was 8.6%, whereas most 
other studies of EF and soy reported FMD’s of 5-6%.  Given that the study participants were, on 
average, prehypertensive, overweight, and mildly dyslipidemic, one might have expected to see 
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mild endothelial dysfunction at baseline rather than a high FMD.  It is possible that the baseline 
FMD measurements in this study were subject to technical error, although there was nothing to 
suggest such problems. 
 Another factor that may have contributed to the lack of a statistically significant 
effect of soy isoflavones on EF was the age and time from menopause of the study subjects.  The 
women in the study had about a 10-year post-menopause mean age (61.5 years), and the time 
from menopause was very close to 10 years (118 months).  As with studies of estrogen and CVD, 
it is possible that in older women many years past menopause, who likely already have significant 
atherosclerotic disease, treatments such as soy phytoestrogens may not be able to achieve very 
much in the way of cardiprotection. 
 
CONCLUSION 
 In summary, the current study suggests that short-term administration of soy 
isoflavone proteins or soy lecithin significantly improves the lipid profile but does not improve 
endothelial function in healthy postmenopausal women.  Study limitations include the small 
sample size, possible hyperglycemic effect, age and time from menopause of study subjects, and 
possible technique issues with the hyperemic response measurements.  Further study is warranted 
to determine if soy isoflavones and/or soy lecithin confer vascular benefit to particular subgroups 
of postmenopausal women, notably those with established cardiac or diabetic risk factors.  Taking 
into account limitations intrinsic to the study design, future studies that modify the sugar content 
of the treatment products, as well as the coordination of the final dose and vascular testing are 
also warranted. 
The clinical use of soy phytoestrogens for the prevention of cardiovascular disease cannot 
be recommended based on the body of evidence to date.  Although soy isoflavones’ 
cardiovascular benefits are biologically plausible and supported by epidemiological evidence, 
clinical evidence is both limited and conflicting. 
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The clinical trials of the cardiovascular effects of isoflavones in postmenopausal women 
to date have examined relatively short-term consumption of isoflavones (usually less than one 
year) beginning at the time of menopause.  It is entirely possible, however, that the 
epidemiological findings of decreased risks of CVD, menopausal symptoms, and breast cancer 
associated with soy consumption result from the cumulative effects of lifelong dietary practices 
rather than perimenopausal consumption alone.  Prospective randomized studies of the effect of 
soy consumption across the lifespan on outcomes such as CVD, breast cancer and menopausal 
symptoms would be informative, although impractical from a logistical standpoint. 
With respect to safety, soy foods have been a staple of Asian diets for centuries, and their 
consumption can be presumed to be relatively benign, provided that the quantities are reasonable.  
Dietary intake of isoflavones in Japan, Taiwan, and Korea are estimated to be 20-150mg/day,69 
which is comparable to or even greater than the quantity in most clinical trials.  
The safety of isoflavone supplements cannot be presumed, however, and has yet to be 
thoroughly studied.  Investigation into side effects and toxicities of soy isoflavones is currently 
underway.  A study of a single ingestion of high-dose isoflavones in 24 healthy postmenopausal 
women revealed minimal clinical toxicity.213  A few isolated episodes of breast tenderness, 
nausea, and pedal edema were reported and may have been related to the study.  Clinical evidence 
regarding the effect of isoflavones on cancers of the breast, endometrium, and prostate is sparse, 
but a possible stimulatory effect on these tissues has been noted.  Until their safety and efficacy 
are established, isoflavone supplements should not be recommended for any condition, including 
menopausal symptoms, CVD, osteoporosis, and breast, endometrial and prostate cancers. 
Although the preponderance of evidence to date does not show that soy protein 
significantly decreases CVD risk as compared to other proteins, the AHA advisory74 still 
concludes that soy products such as tofu, soybeans, and soy butter are likely to  promote 
cardiovascular and overall health because they contain polyunsaturated fats, fiber, vitamins and 
minerals and few saturated fats.  Inclusion of soy protein in the diet is likely to displace other 
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sources of protein that contain saturated fat and cholesterol and thereby promote cardiovascular 
health.  Clinicians should encourage their patients, including perimenpausal women, to include 
soy products as part of a heart-healthy diet emphasizing plant-based nutrition low in saturated fat 
and cholesterol.  With respect to the FDA-approved health claim regarding the cardioprotective 
effects of soy, the FDA should reconsider the appropriateness of this claim in light of recent 
studies that do not substantiate the major cardiovascular benefits of soy protein reported in earlier 
trials. 
Unlike soy protein, the consumption of isoflavone supplements should be discouraged for 
treatment of menopausal symptoms or any other purpose until their safety and efficacy are 
established.  The safety of isoflavones with respect to breast and endometrial cancers is of 
particular importance to treatment decisions involving perimenopausal women and is a crucial 
area for further research. 
With respect to cardiovascular health, further investigation into the precise component of 
the soybean responsible for lipid-lowering is warranted.  Available evidence leans toward soy 
protein and away from isoflavones as the responsible factor, but it could be that another 
component altogether is the active element.  Another area where future research is needed is the 
effect of high protein diets on cardiovascular health.  Studies in which soy protein is consumed in 
addition to rather than instead of animal protein—thereby reducing the consumption of fats and 
carbohydrates—are called for.  In addition, it would be useful to examine how soy isoflavone 
consumption during adolescence and puberty affects cardiovascular disease in perimenopausal 
women, as well as breast and endometrial cancer, and vasomotor instability.  Finally, the soy 
studies that are most needed are those that examine the effects of sustained soy protein and 
isoflavone consumption on specific cardiovascular outcomes, such as coronary heart disease, 
stroke, and thromboembolic events.  Only then can the cardioprotective role for soy protein 
suggested by epidemiological and basic research findings be confirmed or denied. 
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Figure 1: Patient Flow Through Study 
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Table 1.  Baseline Demographic Characteristics (N=25) 
 Variable Mean ± SD 
Age (years) 61.50 ± 8.20 
Time from menopause (months)  118 ± 107.97 
Weight (kg) 70.96 ± 10.10 
Height (m) 164.07 ± 4.75 
BMI (kg/m2) 26.34 ± 3.86 
Systolic Blood Pressure (mmHg) 135.27 ± 17.00 
Diastolic Blood Pressure (mmHg) 77.27 ± 9.43 
Pulse Rate (Per Minute) 76.89 ± 9.72 
Room Temperature (ºF) 72.71 ± 1.49 
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Table 2. Flow Mediated Dilation & Plasma Analyte values at Baseline and After Treatment Assignment 
Variable Baseline 
Soy Protein plus Soy 
Lecithin 
Soy Protein plus 
Placebo Lecithin 
Placebo protein 
plus soy lecithin Double Placebo 
Brachial artery Response      
FMD (%) 8.60 ± 7.20 7.50 ± 9.85 5.51 ± 10.11 5.35 ± 6.13 4.53 ± 7.84 
SARM (%) 0.056 ± 0.046 0.039 ± 0.050 0.028 ± 0.046* 0.028 ± 0.032* 0.017 ± 0.056*  
Lipid panel      
Total Cholesterol 
(mg/dl) 212.64 ± 29.06 188.55 ± 21.83* 184.32 ± 26.5* 179.73 ± 19.16* 181.83 ± 31.37* 
Triglyceride (mg/dl) 99.93 ± 38.96 98.41 ± 44.82 86.91 ± 35.88* 94.45 ± 42.65 89.96 ± 39.52 
LDL (mg/dl) 131.21 ± 27.86 104.55 ± 20.50*‡† 107.77 ± 23.78*† 99.36 ± 18.26‡* 107.43 ± 25.4* 
HDL (mg/dl) 61.86 ± 12.07 64.73 ± 14.45‡ 59.59 ± 14.13 62.00 ± 11.13 56.70 ± 13.25 
HDL/LDL  0.49 ± 0.15 0.64 ± 0.19* 0.58 ± 0.17* 0.65 ± 0.18* 0.55 ± 0.15 
Choline      
Betaine(nmol/ml) 40.57 ± 8.86 98.94 ± 29.63* 36.50 ± 8.90 92.06 ± 28.00* 33.27 ± 11.19* 
Choline(nmol/ml) 7.66 ± 1.73 24.31 ± 8.92* 8.49 ± 2.59 23.84 ± 6.32* 6.89 ± 1.92 
Phosphatidylcholine 
(nmol/ml) 2073.78 ± 195.49 2095.51 ± 223.22 2029.35 ± 263.76 2080.56 ± 220.38 2058.33 ± 250.68 
Blood Pressure      
SBP (mmHg) 135.27 ± 17.00 124.95 ± 15.97* 125.33 ± 12.45* 128.35 ± 17.02 121.61 ± 13.69* 
DBP (mmHg) 77.27 ± 9.43 70.50 ± 9.26* 71.24 ± 9.67* 71.96 ± 9.18 66.87 ± 7.97* 
Isoflavone      
Equol (microM) 1.06 ± 4.03 59.74 ± 101.89*‡† 58.96 ± 103.66*‡† 0.31 ± 1.46 00.00 ± 00.00 
Daidzein (microM) 13.60 ± 22.09 409.91 ± 256.96*‡† 413.77 ± 214.20*‡† 28.32 ± 27.07 26.24 ± 59.81 
Dihydrodaidzein 
(microM) 11.66 ± 25.50 119.10 ± 111.90*‡† 86.35 ± 92.64*‡† 15.77 ± 38.37 11.41 ± 38.63 
O-DMA (microM) 12.25 ± 25.50 166.77 ± 181.85*‡† 119.31 ± 118.88*‡† 26.70 ± 72.19 10.91 ± 28.23 
Genistein (microM) 37.71 ± 56.22 831.31 ± 747.64*‡† 926.18 ± 694.50*‡† 47.78 ± 39.54 60.54 ± 139.98 
Total Isoflavones 
(microM) 76.31 ± 108.58 1586.83± 1045.91*‡† 1604.58 ± 887.34*‡† 118.88 ± 157.62 109.10 ± 244.18 
Values are Mean ± SD  
*P value < 0.05 in paired ttest; ‡P < value 0.05 versus double placebo; †P value < 0.05 versus soy 
lecithin plus placebo 
FMD= Flow-mediated dilation = % diameter change from reference diameter to response diameter 
SARM = Stimulus-adjusted response measure = FMD/flow at 15 s 
SBP = Systolic blood pressure 
DBP = Diastolic blood pressure 
O-DMA = desmethylangolensin 
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Table 3.  Comparison of the Frequency of Occurrence of Side Effects 
Side Effect 
Soy protein & 
soy lecithin 
N (%) 
Soy protein & 
placebo lecithin 
N (%) 
Placebo protein & 
soy lecithin 
N (%) 
Double Placebo  
N (%) 
Leg cramps 2 (9.1%) 1 (4.5%) 2 (8.7%) 3 (13.0%) 
Fever 0 (0%) 0 (0%) 1 (4.3%) 0 (0%) 
Hot flashes 1 (4.5%) 0 (0%) 0 (0%) 0 (0%) 
Headache 3 (13.6%) 2 (9.1%) 3 (13.0%) 3 (13.0%) 
Nausea/vomiting 1 (4.5%) 3 (13.6%) 1 (4.3%) 0 (0%) 
Weight gain 5 (22.7%) 4 (18.2%) 5 (21.8%) 6 (26.1%) 
Hand or feet swelling 0 (0%) 1 (4.5%) 1 (4.3%) 1 (4.3%) 
Muscle aches and pains 0 (0%) 1 (4.5%) 3 (13.0%) 0 (0%) 
Joint pain 0 (0%) 0 (0%) 2 (8.7%) 0 (0%) 
Lack of sleep 0 (0%) 1 (4.5%) 0 (0%) 2 (8.7%) 
Feeling depressed  0 (0%) 0 (0%) 1 (4.3%) 1 (4.3%) 
Hoarseness 1 (4.5%) 1 (4.5%) 4 (17.4%) 0 (0%) 
Excessive sweating 1 (4.5%) 1 (4.5%) 0 (0%) 1 (4.3%) 
Skin rash 1 (4.5%) 1 (4.5%) 0 (0%) 1 (4.3%) 
Urinary tract infection 1 (4.5%) 1 (4.5%) 0 (0%) 0 (0%) 
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